Exhibiting at VIV Asia 2025

The United Laboratories International Holdings Limited (TUL) is a leading vertically integrated pharmaceutical company headquartered in Yuen Long, Hong Kong. With a diversified product portfolio, extensive production capacity, and a global market presence, TUL has established itself as one of China’s most prominent manufacturers and exporters of antibiotic and generic pharmaceutical products.

Company Overview

Founded in 1990, TUL has grown from a domestic active pharmaceutical ingredient (API) producer into a full-fledged pharmaceutical conglomerate encompassing R&D, manufacturing, marketing, and international distribution. The company was listed on the Hong Kong Stock Exchange in June 2007 (HKEX Stock Code: 3933), and its operations span multiple provinces in Mainland China and export markets worldwide.

Core Business Segments

TUL operates primarily across three business segments:

• Intermediate and Bulk Medicines (API)

  • Penicillin series: Amoxicillin, Ampicillin, Penicillin G
  • Cephalosporins: Ceftriaxone, Cefuroxime
  • Production of key intermediates such as 6-APA

• Preparation Products

  • Oral antibiotics (capsules, tablets)
  • Injectable antimicrobials
  • Eye drops and other specialty generics
  • Cardiovascular, antiviral, anti-hepatitis, and diabetic drugs

• Research and Development

  • Focused on high-end generics, new drug delivery systems, and bioequivalency studies
  • Investment in biosimilars and new chemical entities (NCEs)

Product Categories

TUL manufactures over 200 pharmaceutical products across 12 therapeutic categories:

• Oral Antibiotics: Amoxicillin Capsules, Ampicillin Capsules, Cefdinir Capsules
• Injectable Antimicrobials: Ceftriaxone Sodium for Injection, Cefotaxime, Ceftazidime
• Cardiovascular Drugs: Amlodipine Besylate Tablets, Losartan Potassium Tablets
• Anti-diabetic Medications: Metformin Hydrochloride Tablets, Glimepiride
• Nervous System: Alprazolam Tablets, Lorazepam
• Antiviral Drugs: Lamivudine, Entecavir
• Hepatitis B Drugs: Adefovir Dipivoxil
• Vitamin and Nutritionals: Folic Acid, Multivitamin tablets
• Veterinary Products: Select penicillin APIs
• Vacant Gelatin Capsules: Supply for contract filling

Manufacturing Infrastructure

TUL owns and operates seven major production sites across China including:

• Zhuhai – Modern solid dosage manufacturing facility
• Chengdu – Major API production base
• Inner Mongolia – Key site for penicillin and 6-APA production
• Heyuan (Guangdong) – Antibiotic and cephalosporin manufacturing hub

These facilities comply with international Good Manufacturing Practices (GMP) and are certified by regulatory bodies including:

• China’s National Medical Products Administration (NMPA)
• European Directorate for the Quality of Medicines (EDQM)
• U.S. Food and Drug Administration (FDA) (select APIs)
• World Health Organization (WHO) prequalification (selected products)

Global Reach and Export Markets

TUL exports its products to over 50 countries across Asia, Africa, the Middle East, Europe, and Latin America. The company has built strong B2B partnerships with:

• Multinational generic drug companies
• Public health procurement agencies
• Hospital groups and private wholesalers

Export performance:

• 2022 API export volume: Over 3,000 metric tons
• Preparation products shipped globally: Approx. 200 million units/year
• Top export regions: India, Vietnam, Egypt, Brazil, South Africa

TUL is also an approved supplier to United Nations agencies and international NGOs for antimicrobial procurement.

Financial Highlights

As reported in its FY2022 annual results:

• Revenue: HKD 8.3 billion (~USD 1.05 billion)
• Net Profit: HKD 960 million (~USD 122 million)
• R&D expenditure: HKD 310 million (~USD 39 million)
• API revenue share: ~55%
• Finished preparations share: ~40%

The company continues to maintain a strong capital base and operating cash flow to support expansion in both domestic and international markets.

R&D and Innovation

TUL operates two state-level R&D centers and collaborates with leading universities for formulation innovation. Core focus areas include:

• Oral solid controlled-release systems
• Parenteral long-acting injectables
• Bioequivalence studies for generic drug approval in EU/US markets
• Development of biosimilars and monoclonal antibodies

As of 2023, TUL holds over 250 patents and has filed more than 100 ANDAs (Abbreviated New Drug Applications) globally.

Certifications and Quality Compliance

TUL facilities are certified under:

• EU-GMP and CEP (Certificate of Suitability) for European markets
• cGMP by U.S. FDA (selected sites)
• ISO 9001, ISO 14001, and OHSAS 18001 for quality, environmental, and safety management

The company maintains a robust pharmacovigilance program and adheres to strict batch traceability and recall systems in line with global standards.

Corporate Responsibility and ESG Initiatives

TUL actively promotes green manufacturing and sustainability through:

• Closed-loop water recycling systems in API plants
• Biomass and natural gas energy sources
• Waste reduction in antibiotic fermentation processes

It also supports healthcare outreach and charitable initiatives focused on antibiotic education and medicine access in rural China and Southeast Asia.

Strategic Outlook

TUL aims to:

• Expand into high-margin specialty generics and injectable biologics
• Increase global sales of branded generics under the TUL label
• Enter new markets in Africa, CIS, and Central America
• Pursue international regulatory approvals for key antibiotic and antiviral products

With a robust product pipeline, global regulatory footprint, and strong API-to-finished-dose integration, The United Laboratories International Holdings Limited continues to lead China’s pharmaceutical export segment while evolving into a global generic powerhouse.